Comparative Efficacy of Dapagliflozin and Empagliflozin of a Fixed Dose in Heart Failure: A Network Meta-Analysis.

ABSTRACT:

Background

The efficacy of dapagliflozin and empagliflozin in sodium-glucose cotransport-2 inhibitors (SGLT-2i) in patients with heart failure (HF) has been discovered. However, which drug could improve varied prognostic outcomes has not been elucidated. Hence, we compared their efficacies on the prognostic improvement of HF.

Methods

Databases including PubMed, EMBASE, Scopus, Google Scholars, and the Cochrane Library were searched for all related randomized controlled trials (RCTs) published from inception to 13 October 2021. Network meta-analyses were performed to generate matrices to show the effect size for pairwise comparison regarding all the interventions.

Results

Eventually a total of 11 RCTs were included in this study. For the primary endpoints, dapagliflozi

SUBMITTER: Shi Z 

PROVIDER: S-EPMC9013819 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature